MDx Startup Xagenic Closes on $10M Series A Financing Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics startup Xagenic today announced the closing of a Series A financing round that raised C$10 million (US$10 million).

CTI Life Sciences Fund and the Ontario Emerging Technologies Fund led the round, with "significant participation" by Qiagen, Toronto-based Xagenic said. The money will go toward the development of a decentralized molecular diagnostic platform for use in doctors' offices, clinics, and hospital systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.